MA26889A1 - Composition pharmaceutique pour le traitement de la douleur aigue chronique et/ ou neuropathique et des migraines - Google Patents

Composition pharmaceutique pour le traitement de la douleur aigue chronique et/ ou neuropathique et des migraines

Info

Publication number
MA26889A1
MA26889A1 MA26846A MA26846A MA26889A1 MA 26889 A1 MA26889 A1 MA 26889A1 MA 26846 A MA26846 A MA 26846A MA 26846 A MA26846 A MA 26846A MA 26889 A1 MA26889 A1 MA 26889A1
Authority
MA
Morocco
Prior art keywords
migraines
treatment
pharmaceutical composition
neuropathic pain
acute chronic
Prior art date
Application number
MA26846A
Other languages
English (en)
Inventor
Thomas O'neill Brian
Bradley Sands Steven
Jacob Watsky Eric
Wadsworth Coe Jotham
Patrick Harrigan Edmund
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26889A1 publication Critical patent/MA26889A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA26846A 2000-04-07 2002-10-02 Composition pharmaceutique pour le traitement de la douleur aigue chronique et/ ou neuropathique et des migraines MA26889A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19573800P 2000-04-07 2000-04-07

Publications (1)

Publication Number Publication Date
MA26889A1 true MA26889A1 (fr) 2004-12-20

Family

ID=22722582

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26846A MA26889A1 (fr) 2000-04-07 2002-10-02 Composition pharmaceutique pour le traitement de la douleur aigue chronique et/ ou neuropathique et des migraines

Country Status (35)

Country Link
US (2) US20010036943A1 (fr)
EP (1) EP1272218B1 (fr)
JP (1) JP2003530345A (fr)
KR (1) KR20030040201A (fr)
CN (1) CN1468111A (fr)
AP (1) AP2002002642A0 (fr)
AR (1) AR027773A1 (fr)
AT (1) ATE291438T1 (fr)
AU (1) AU3768001A (fr)
BG (1) BG107138A (fr)
BR (1) BR0109837A (fr)
CA (1) CA2405142A1 (fr)
CR (1) CR6767A (fr)
CZ (1) CZ20023214A3 (fr)
DE (1) DE60109589T2 (fr)
EA (1) EA004930B1 (fr)
EE (1) EE200200579A (fr)
ES (1) ES2236185T3 (fr)
GT (1) GT200100055A (fr)
HU (1) HUP0301822A3 (fr)
IL (1) IL152076A0 (fr)
IS (1) IS6560A (fr)
MA (1) MA26889A1 (fr)
MX (1) MXPA02009817A (fr)
NO (1) NO20024734D0 (fr)
OA (1) OA12241A (fr)
PA (1) PA8515001A1 (fr)
PE (1) PE20011307A1 (fr)
PL (1) PL365957A1 (fr)
SK (1) SK13952002A3 (fr)
SV (1) SV2002000377A (fr)
TN (1) TNSN01053A1 (fr)
WO (1) WO2001076576A2 (fr)
YU (1) YU74602A (fr)
ZA (1) ZA200207996B (fr)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69722426T3 (de) 1996-07-24 2015-05-07 Warner-Lambert Company LLC (n.Ges. des Staates Delaware) Isobutylgaba und dessen derivate zur schmerzbehandlung
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
WO2002026020A2 (fr) * 2000-09-26 2002-04-04 The Brigham And Women's Hospital, Inc. Antidepresseurs tricycliques et leurs analogues comme anesthesiques et analgesiques locaux de longue duree
US7074961B2 (en) 2000-09-26 2006-07-11 The Brigham And Women's Hospital, Inc. Antidepressants and their analogues as long-acting local anesthetics and analgesics
JP2004527545A (ja) * 2001-04-20 2004-09-09 ファイザー・プロダクツ・インク １，３−置換インデンおよびアリール縮合アザ多環式化合物の調製方法
ES2632544T3 (es) * 2001-06-07 2017-09-14 Analgesic Neuropharmaceuticals, Llc Tratamiento de dolor neuropático con el antagonista del receptor de N-metil-D-aspartato (NMDA) dextrometorfano
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20040138239A1 (en) * 2001-08-23 2004-07-15 Bruce Frome Compositions and methods for targeting cerebral circulation and treatment of headache
EP1419161A1 (fr) 2001-08-24 2004-05-19 PHARMACIA & UPJOHN COMPANY Heteroaryl-7-aza 2.2.1]bicycloheptanes substitues destines au traitement de maladies
IL160884A0 (en) 2001-10-02 2004-08-31 Upjohn Co Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
JP2005510523A (ja) 2001-11-09 2005-04-21 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー アザ二環式フェニル縮合複素環式化合物、及びα７ＮＡＣＨＲリガンドとしての当該化合物の使用
WO2003049753A1 (fr) * 2001-12-13 2003-06-19 Council Of Scientific And Industrial Research Le zingiber officinale de linn et ses extraits et fractions en tant que renforçateurs de biodisponibilite
EP1471910A2 (fr) * 2002-01-17 2004-11-03 Neurogen Corporation Analogues de quinazoline-4-ylamine substitues comme modulateurs de receptors de la capsaicin
WO2003066040A1 (fr) * 2002-02-05 2003-08-14 Ajinomoto Co.,Inc. Compositions medicinales contenant une gabapentine ou une pregabaline et antagoniste a canal de calcium de type n
US20050096395A1 (en) * 2002-02-12 2005-05-05 Rao Srinivas G. Methods of treating attention deficit/hyperactivity disorder (adhd)
US6852716B2 (en) 2002-02-15 2005-02-08 Pfizer Inc Substituted-aryl compounds for treatment of disease
US6858613B2 (en) 2002-02-19 2005-02-22 Pfizer Inc. Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
BR0307782A (pt) 2002-02-19 2005-01-04 Upjohn Co Compostos azabiciclo para o tratamento de doença
EP1499309A4 (fr) * 2002-04-24 2008-05-28 Cypress Bioscience Inc Prevention et traitement de troubles somatiques fonctionnels, y-compris les troubles lies au stress
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US20040014681A1 (en) * 2002-05-14 2004-01-22 Ralph Ryback Method for treating dermatoses and tissue damage
WO2003097043A1 (fr) * 2002-05-15 2003-11-27 Abbott Laboratories Traitement de la douleur neuropathique
WO2003096991A2 (fr) 2002-05-17 2003-11-27 Othera Pharmaceuticals, Inc. Amelioration de l'evolution des cataractes et d'autres maladies ophtalmiques
JP2006509735A (ja) * 2002-10-17 2006-03-23 ノバルティス アクチエンゲゼルシャフト オクスカルバゼピンまたはその誘導体およびｃｏｘ２インヒビターからなる疼痛処置用医薬組成物
WO2004050688A1 (fr) 2002-12-02 2004-06-17 Xenome Ltd Nouveaux peptides de $g(x)-conotoxine (-ii)
EP1572725B1 (fr) 2002-12-02 2012-02-29 Xenome Ltd Peptides de chi-conotoxine presentant l'acide pyroglutamique n-terminale
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
DK1578422T3 (da) 2002-12-20 2007-07-02 Niconovum Ab Fysisk og kemisk stabilt nikotin-indeholdende partikelholdigt materiale
EP1599221B1 (fr) * 2003-03-06 2011-12-28 Botulinum Toxin Research Associates, Inc. Traitement des cephalees et des douleurs faciales chroniques associees a la sinusite au moyen de toxine botulinique
EA008705B1 (ru) * 2003-04-08 2007-06-29 Алгоркс Фармасьютикалз, Инк. Получение и очистка синтетического капсаицина
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2004105690A2 (fr) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Traitement de douleurs chroniques au moyen de chimiotherapie ou de radiotherapie
WO2005000806A2 (fr) 2003-06-10 2005-01-06 Georgetown University Ligands pour les recepteurs de l'acetylcholine nicotinique, et procedes de production et d'utilisation de ces ligands
US20050004219A1 (en) * 2003-07-01 2005-01-06 Medtronic, Inc. Pump systems including injectable gabapentin compositions
US20050004221A1 (en) * 2003-07-01 2005-01-06 Medtronic, Inc. Intrathecal gabapentin compositions
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2005032556A1 (fr) 2003-10-02 2005-04-14 Elan Pharmaceuticals, Inc. Methode de soulagement de la douleur
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
AU2004291082A1 (en) * 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
HU230403B1 (hu) * 2003-12-19 2016-04-28 Pál Kocsis Nátrium csatorna blokkoló és szerotonin újrafelvétel gátló tartalmú gyógyszerkészítmény
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
WO2005123043A2 (fr) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations de sumatriptan absorbables au travers des membranes biologiques, et methodes de production et d'utilisation desdites formulations
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
JP2008517927A (ja) * 2004-10-21 2008-05-29 ユニバーシティー オブ アイオワ リサーチ ファンデーション ｉｎｓｉｔｕ制御放出薬剤送達システム
US20080176873A1 (en) * 2004-11-10 2008-07-24 Trinity Laboratories, Inc. Novel Pharmaceutical Compositions for Treating Acquired Chronic Pain and Associated Dysphoria
BRPI0516912A2 (pt) * 2004-11-24 2009-06-23 Algorx Pharmaceuticals Inc formulação a base do capsaicinoide em gel e usos da mesma
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
EP1881959A1 (fr) 2005-05-20 2008-01-30 Janssen Pharmaceutica N.V. Procede de fabrication de derives de sulfamide
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
JP5694645B2 (ja) 2006-03-16 2015-04-01 ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ 改善された嗅ぎたばこ組成物
JP2007308403A (ja) * 2006-05-17 2007-11-29 Kenji Yoshida 皮膚外用剤
JP2009537635A (ja) 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
CN101511388B (zh) * 2006-07-17 2012-10-24 特拉维夫大学拉莫特有限公司 含有精神药物或gaba激动剂和有机酸的缀合物以及它们在治疗疼痛和其它cns疾病中的用途
WO2008020651A1 (fr) * 2006-08-17 2008-02-21 Kyushu University, National University Corporation antagoniste de récepteur P2X4
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
PL2081562T3 (pl) * 2006-09-20 2017-05-31 The Board Of Regents Of The University Of Texas System Sposoby dostarczania lotnych środków znieczulających do znieczulenia regionalnego i/lub zmniejszania bólu
US20100048605A1 (en) * 2006-12-11 2010-02-25 University Of Kentucky Research Foundation Synergistic effects of combinations of nornicotine and opioids for the treatment of pain
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
JP5647519B2 (ja) 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成
EP2381834A2 (fr) * 2008-01-31 2011-11-02 Fund for Medical Research Development of Infrastructure & Health Services Rambam Medical Center Procédé de prédiction d'efficacité d'analgésique
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
EP3000462A1 (fr) * 2008-04-28 2016-03-30 Zogenix, Inc. Compositions inédites destinées au traitement de la migraine
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
PE20130243A1 (es) 2010-06-15 2013-03-22 Gruenenthal Chemie Combinacion farmaceutica
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
ME02874B (fr) 2010-12-22 2018-04-20 Purdue Pharma Lp Formes posologiques à libération contrôlée enchâssées et inviolables
CN103327969A (zh) 2010-12-23 2013-09-25 普渡制药公司 抗篡改固体口服剂型
US20130324608A1 (en) * 2011-02-18 2013-12-05 Yuanlong Pan Methods and compositions for treating, reducing or preventing damage to the nervous system of animals
ES2387973B1 (es) * 2011-03-18 2013-10-01 Dr Healthcare España, S. L. Composiciones tópicas que contienen diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que comportan un aumento del dolor.
US8580850B2 (en) 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
AU2013302468B2 (en) * 2012-08-16 2017-08-24 Janssen Pharmaceutica Nv Substituted pyrazoles as N-type calcium channel blockers
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CA3042642A1 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2015095391A1 (fr) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération prolongée
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (fr) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus a liberation immediate
EP3209282A4 (fr) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
CN104758933A (zh) * 2014-10-29 2015-07-08 吴鑫欣 治疗神经卡压、神经瘤疼痛的药物和给药系统
EP3600385A4 (fr) * 2017-03-22 2021-04-07 Bonti, Inc. Neurotoxines de botulinum pour le traitement de lésions traumatiques
WO2018183320A1 (fr) * 2017-03-31 2018-10-04 Depco, Inc. Mastic thérapeutique à analgésiques et/ou révulsifs
US10463638B2 (en) * 2017-04-12 2019-11-05 Synergistic Therapeutics, Llc Therapeutic neuropathic pain lotion
KR101944113B1 (ko) 2017-09-28 2019-01-30 동의대학교 산학협력단 급성 안면통증 예방 및 개선용 조성물
KR102156627B1 (ko) 2018-12-20 2020-09-16 동의대학교 산학협력단 보스웰리아 추출물 및 산자나무 추출물을 포함하는 급성 안면통증 예방 및 개선용 조성물
KR102156438B1 (ko) 2018-12-20 2020-09-16 동의대학교 산학협력단 급성 안면통증 예방 및 개선용 조성물
CN115054601B (zh) * 2022-03-21 2024-04-26 中山大学附属第三医院 一种可注射的缓释镇痛复合物及其制备方法、应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018798A1 (fr) * 1996-10-30 1998-05-07 Pfizer Inc. Derives de la cytisine ou derives azabicycliques condenses avec la pyridone, leur preparation et leur utilisation dans le traitement des toxicomanies
EP0955301A3 (fr) * 1998-04-27 2001-04-18 Pfizer Products Inc. Dérivés de 7-aza-bicyclo[2.2.1]-heptane, leur préparation et utilisation sur la base d'affinité pour les recepteurs de l'acetylcholine nicotinique neuronaux
ES2213354T3 (es) * 1998-04-29 2004-08-16 Pfizer Products Inc. Compuestos azapoliciclicos condensados con arilo.
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
US20010036943A1 (en) 2001-11-01
OA12241A (en) 2004-01-27
EA200200910A1 (ru) 2003-02-27
SK13952002A3 (sk) 2003-12-02
AR027773A1 (es) 2003-04-09
ATE291438T1 (de) 2005-04-15
ZA200207996B (en) 2003-10-20
EP1272218A2 (fr) 2003-01-08
NO20024734D0 (no) 2002-10-02
AP2002002642A0 (en) 2002-12-31
BG107138A (en) 2003-05-30
EP1272218B1 (fr) 2005-03-23
TNSN01053A1 (fr) 2005-11-10
MXPA02009817A (es) 2003-03-27
PE20011307A1 (es) 2001-12-28
IS6560A (is) 2002-09-20
WO2001076576A2 (fr) 2001-10-18
PA8515001A1 (es) 2002-02-21
HUP0301822A3 (en) 2005-06-28
IL152076A0 (en) 2003-05-29
SV2002000377A (es) 2002-07-03
US20030133951A1 (en) 2003-07-17
CA2405142A1 (fr) 2001-10-18
EA004930B1 (ru) 2004-10-28
CR6767A (es) 2004-06-09
DE60109589D1 (de) 2005-04-28
JP2003530345A (ja) 2003-10-14
YU74602A (sh) 2006-05-25
GT200100055A (es) 2001-12-31
ES2236185T3 (es) 2005-07-16
BR0109837A (pt) 2003-01-21
DE60109589T2 (de) 2005-09-01
AU3768001A (en) 2001-10-23
PL365957A1 (en) 2005-01-24
HUP0301822A2 (hu) 2003-11-28
KR20030040201A (ko) 2003-05-22
CN1468111A (zh) 2004-01-14
EE200200579A (et) 2004-06-15
CZ20023214A3 (cs) 2003-11-12
WO2001076576A3 (fr) 2002-06-20

Similar Documents

Publication Publication Date Title
MA26889A1 (fr) Composition pharmaceutique pour le traitement de la douleur aigue chronique et/ ou neuropathique et des migraines
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
MA25775A1 (fr) Combinaison des bacteries d'acide lactique et son utilisation pour la prevention et/ou le traitement des infections et des etats inflammatoires.
DZ2675A1 (fr) Association pharmaceutique pour le traitement d'undysfunctionnement sexuel et compositions la conte nant.
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
MA26655A1 (fr) Composition pour prevention et/ou traitement d'osteoporose et d'alterations dues au syndrome menopause
PT956858E (pt) Composicoes farmaceuticas contendo lactobacilos para o tratamento de infeccoes vaginais
MA26618A1 (fr) Composes et compositions pharmaceutiques pour le traitement du paludisme
FR2816513B1 (fr) Valve sous-cutanee pour le traitement de l'hydrocephalie et ses dispositifs de reglage
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
FR2815541B1 (fr) Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
MA25234A1 (fr) Vibromasseur pour le soulagement des maux et de la douleur.
FR2812197B1 (fr) Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
MA26896A1 (fr) Utilisation de compositions d'antibiotiques azalides pour le traitement ou la prevention d'une infection par des bacteries ou protozoaires chez des mammiferes
DZ3393A1 (fr) Procede de detection de composes apropries pour le traitement et/ou la prophylaxie de l'obesite
FR2823307B1 (fr) Procede et micropresse pour caracteriser les proprietes mecaniques des solides pharmaceutiques
FR2705966B1 (fr) Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
FR2758465B1 (fr) Composition pour le traitement de l'amiante
DZ3225A1 (fr) Methode et compositions pour le traitement des maladies pulmonaires
DZ2012A1 (fr) Benzamides pour le traitement de dégénérescences neurologiques.
FR2808687B1 (fr) Medicament contenant des substances polysaccharidiques pour l'activation de l'apoptose
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
DZ2564A1 (fr) Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.
FR2869539B1 (fr) Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose